The ability of azithromycin to impact the production of inflammatory mediators through its inhibition of NF-κB and other pro-inflammatory signaling pathways suggests the potential for benefit in counteracting the hyperinflammatory state that manifests through neutrophil influx, lung inflammation, cytokine storm, and hypercoagulation. Here, NFKB1 is linked to thrombophilia.